CheLi Lin - VitaSpring Biomedical Chief Officer

All Insiders . USA . 
Stock . VitaSpring Biomedical Co . Stakeholders . Insider . CheLi Lin
VSBC Stock  USD 1.00  0.00  0.00%   

Insider

CheLi Lin is Chief Officer of VitaSpring Biomedical Co
Phone949 202 9235
Webhttps://www.vitaspringbio.com

VitaSpring Biomedical Management Efficiency

The company has return on total asset (ROA) of 0.4098 % which means that it generated a profit of $0.4098 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8416 %, meaning that it created $0.8416 on every $100 dollars invested by stockholders. VitaSpring Biomedical's management efficiency ratios could be used to measure how well VitaSpring Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.
VitaSpring Biomedical Co currently holds 375.5 K in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. VitaSpring Biomedical has a current ratio of 4.15, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist VitaSpring Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, VitaSpring Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VitaSpring Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VitaSpring to invest in growth at high rates of return. When we think about VitaSpring Biomedical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Robert CFASatellos Bioscience
N/A
Gregory MadisonShield Therapeutics plc
55
Francis MBASatellos Bioscience
68
Justin CahillParadigm Biopharmaceuticals Lim
N/A
BA ASiAImugene Limited
67
Joseph GuercioNuo Therapeutics
51
Qun LuKintor Pharmaceutical Limited
57
ACA BScImugene Limited
56
Jos MDShield Therapeutics plc
N/A
Grad BScParadigm Biopharmaceuticals Lim
64
Anthony GoodImugene Limited
N/A
David CPANuo Therapeutics
61
Beverley HuttmannParadigm Biopharmaceuticals Lim
N/A
Christian MDShield Therapeutics plc
56
CPA CMASatellos Bioscience
71
MS MDParadigm Biopharmaceuticals Lim
66
Marco PolizziParadigm Biopharmaceuticals Lim
N/A
William JaroszSatellos Bioscience
67
Nathan CAImugene Limited
N/A
Michael ImperialeParadigm Biopharmaceuticals Lim
N/A
Wai FCSKintor Pharmaceutical Limited
68
The company was formerly known as Shemn Corp. and changed its name to VitaSpring Biomedical Co. Ltd. was incorporated in 2016 and is headquartered in Irvine, California. Vitaspring Biomedical operates under Biotechnology classification in the United States and is traded on OTC Exchange. VitaSpring Biomedical Co [VSBC] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.

Management Performance

Return On Equity0.84
Return On Asset0.41

VitaSpring Biomedical Management Team

Elected by the shareholders, the VitaSpring Biomedical's board of directors comprises two types of representatives: VitaSpring Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VitaSpring. The board's role is to monitor VitaSpring Biomedical's management team and ensure that shareholders' interests are well served. VitaSpring Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VitaSpring Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
ChengHsiang Kao, CEO Sec
YenHsun Chen, Technical VicePres
CheLi Lin, Chief Officer

VitaSpring Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is VitaSpring Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.84
Return On Asset0.41
Profit Margin0.19 %
Operating Margin0.24 %
Current Valuation2.89 B
Shares Outstanding206.52 M
Shares Owned By Insiders58.70 %
Price To Book1,622 X
Price To Sales558.27 X
Revenue5.61 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Other Information on Investing in VitaSpring Pink Sheet

VitaSpring Biomedical financial ratios help investors to determine whether VitaSpring Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VitaSpring with respect to the benefits of owning VitaSpring Biomedical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY